As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in ...

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is ...

While radiopharmaceuticals have attracted significant interest in recent years thanks to their cancer-fighting prowess, the ...

OmniaBio, a CDMO focused on cell and gene therapies, debuted a new manufacturing facility it claims to be the largest of its ...

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, ...

Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The more healthcare professionals (HCPs) know the pharma industry, the more they trust the pharma industry. That is the claim ...

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...